

Peter S Nelson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5005894/peter-s-nelson-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162 papers	15,096 citations	52 h-index	122 g-index
186 ext. papers	19,231 ext. citations	10.8 avg, IF	6.21 L-index

#	Paper	IF	Citations
162	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort. <i>Journal of Urology</i> , 2021 , 101097JU00000000000002354	2.5	
161	Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. <i>Nature Communications</i> , 2021 , 12, 1426	17.4	40
160	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. <i>Prostate</i> , 2021 , 81, 418-426	4.2	3
159	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021 , 12, 1979	17.4	11
158	Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. <i>JCI Insight</i> , 2021 , 6,	9.9	5
157	Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	4
156	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. <i>Clinical Cancer Research</i> , 2021 , 27, 4923-4936	12.9	6
155	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. <i>Cancer Research</i> , 2021 , 81, 4736-4750	10.1	2
154	Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer. <i>Nature Communications</i> , 2021 , 12, 4217	17.4	4
153	Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 759-774	12.9	9
152	Genomic and phenotypic heterogeneity in prostate cancer. <i>Nature Reviews Urology</i> , 2021 , 18, 79-92	5.5	41
151	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. <i>JAMA Oncology</i> , 2021 , 7, 107-110	13.4	34
150	Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. <i>PLoS ONE</i> , 2021 , 16, e0245602	3.7	1
149	The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. <i>Endocrine-Related Cancer</i> , 2021 , 28, T51-T66	5.7	6
148	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. <i>Urology Practice</i> , 2021 , 8, 576-582	0.8	
147	Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. <i>JAMA Oncology</i> , 2021 ,	13.4	8
146	Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	1

145	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2021 ,	6.4	1
144	Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer. <i>Journal of Pathology</i> , 2021 , 255, 425-437	9.4	2
143	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021 , 12, 5775	17.4	6
142	Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer: Is Rising Utilization Justified by Evidence?. <i>JAMA Oncology</i> , 2021 , 7, 59-60	13.4	1
141	Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. <i>JCI Insight</i> , 2021 , 6,	9.9	1
140	HPV16 induces penile intraepithelial neoplasia and squamous cell carcinoma in transgenic mice: first mouse model for HPV-related penile cancer. <i>Journal of Pathology</i> , 2020 , 251, 411-419	9.4	8
139	Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. <i>Neoplasia</i> , 2020 , 22, 253-262	6.4	9
138	Targeting RET Kinase in Neuroendocrine Prostate Cancer. <i>Molecular Cancer Research</i> , 2020 , 18, 1176-1188	18.6	11
137	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. <i>PLoS ONE</i> , 2020 , 15, e0233260	3.7	29
136	Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN. <i>Cancer Genetics</i> , 2020 , 243, 11-18	2.3	7
135	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1549-1557	2.2	26
134	Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2020 , 26, 4882-4891	12.9	14
133	Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. <i>Cell Reports</i> , 2020 , 31, 107669	10.6	55
132	A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments. <i>Prostate</i> , 2020 , 80, 491-499	4.2	2
131	Deconstructing tumor heterogeneity: the stromal perspective. <i>Oncotarget</i> , 2020 , 11, 3621-3632	3.3	12
130	Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages 2020 , 8,		3
129	Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1667-1677	12.9	11
128	Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	6

127	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. <i>Oncogene</i> , 2020 , 39, 6935-6949	9.2	19
126	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020 , 6, e203187	13.4	14
125	Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3740-3742	2.2	9
124	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. <i>European Urology</i> , 2020 , 77, 144-155	10.2	23
123	and COVID-19: Serendipity or Opportunity for Intervention?. <i>Cancer Discovery</i> , 2020 , 10, 779-782	24.4	231
122	PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer. <i>Cancer Research</i> , 2019 , 79, 5668-5680	10.1	5
121	Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. <i>Nature Cell Biology</i> , 2019 , 21, 238-250	23.4	118
120	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 438-445	6.2	12
119	EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. <i>EMBO Journal</i> , 2019 , 38,	13	33
118	Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. <i>Prostate</i> , 2019 , 79, 1326-1337	4.2	10
117	Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer. <i>Cancer Research</i> , 2019 , 79, 3320-3331	10.1	22
116	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 11428-11436	11.5	383
115	Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 560-568	6.2	7
114	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. <i>Prostate</i> , 2019 , 79, 701-708	4.2	9
113	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , 2019 , 79, 2580-2592	10.1	42
112	Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion. <i>Prostate</i> , 2019 , 79, 1530-1542	4.2	3
111	The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	29
110	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2019 , 25, 6916-6924	12.9	94

109	Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. <i>JCI Insight</i> , 2019 , 5,	9.9	46
108	Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4245-4260	15.9	39
107	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4492-4505	15.9	102
106	The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells. <i>Molecular Cancer Research</i> , 2019 , 17, 321-331	6.6	19
105	Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 426-439	12.9	27
104	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , 2019 , 129, 192-208	15.9	157
103	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. <i>European Urology</i> , 2018 , 74, 211-217	10.2	22
102	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 364-372	6.2	29
101	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , 2018 , 50, 645-651	36.3	380
100	Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. <i>Journal of Urology</i> , 2018 , 199, 1494-1501	2.5	17
99	Retinol dehydrogenase 11 is essential for the maintenance of retinol homeostasis in liver and testis in mice. <i>Journal of Biological Chemistry</i> , 2018 , 293, 6996-7007	5.4	11
98	Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018 , 8,	5.4	28
97	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018 , 13, e0198389	3.7	51
96	A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. <i>Neoplasia</i> , 2018 , 20, 789-799	6.4	15
95	Microsatellite instability in prostate cancer by PCR or next-generation sequencing 2018 , 6, 29		58
94	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. <i>Cell</i> , 2018 , 173, 1770-1782.e14	56.2	256
93	Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. <i>Cell</i> , 2018 , 174, 433-447.e19	56.2	155
92	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. <i>Cancer Research</i> , 2018 , 78, 4716-4730	10.1	33

91	Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects. <i>F1000Research</i> , 2018 , 7,	3.6	22
90	Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. <i>Oncotarget</i> , 2018 , 9, 6550-6561	3.3	13
89	ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. <i>Nature Medicine</i> , 2018 , 24, 1887-1898	50.5	63
88	Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. <i>Molecular Oncology</i> , 2017 , 11, 140-150	7.9	17
87	Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. <i>Molecular Cancer Research</i> , 2017 , 15, 521-531	6.6	11
86	LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics. <i>Prostate</i> , 2017 , 77, 654-674	14.2	128
85	Neoadjuvant Enzalutamide Prior to Prostatectomy. <i>Clinical Cancer Research</i> , 2017 , 23, 2169-2176	12.9	50
84	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2017 , 72, 448-454	10.2	49
83	ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. <i>Scientific Reports</i> , 2017 , 7, 1109	4.9	14
82	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. <i>Cell Reports</i> , 2017 , 19, 2045-2059	10.6	72
81	DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes. <i>Molecular Cancer Research</i> , 2017 , 15, 842-851	6.6	8
80	Anti-Depressant Therapy Brightens the Outlook for Prostate Cancer Bone Metastases. <i>Cancer Cell</i> , 2017 , 31, 303-305	24.3	5
79	Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. <i>Cancer Cell</i> , 2017 , 32, 474-489.e6	24.3	280
78	Prostate Cancer Screening in a New Era of Genetics. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 625-628	3.3	19
77	The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer. <i>Cancer Discovery</i> , 2017 , 7, 673-674	24.4	5
76	Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 222-227	4	26
75	Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. <i>Oncotarget</i> , 2017 , 8, 6179-6192	3.3	14
74	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. <i>Journal of Urology</i> , 2016 , 195, 313-20	2.5	93

73	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. <i>European Urology Focus</i> , 2016 , 2, 180-188	5.1	52
72	Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016 , 33, 77	3.7	8
71	Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations. <i>Molecular Cancer Research</i> , 2016 , 14, 374-84	6.6	25
70	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1402-18	2.2	666
69	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. <i>Nature Medicine</i> , 2016 , 22, 369-78	50.5	425
68	Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence. <i>Journal of Molecular Diagnostics</i> , 2016 , 18, 215-24	5.1	7
67	Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases. <i>Clinical and Experimental Metastasis</i> , 2016 , 33, 239-48	4.7	23
66	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 69, 992-5	10.2	175
65	High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. <i>Journal of Molecular Diagnostics</i> , 2016 , 18, 131-43	5.1	5
64	Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer. <i>Cancer Research</i> , 2016 , 76, 283-92	10.1	73
63	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. <i>PLoS ONE</i> , 2016 , 11, e0165236	3.7	19
62	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. <i>Oncotarget</i> , 2016 , 7, 82504-82510	3.3	47
61	A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. <i>Oncotarget</i> , 2016 , 7, 52888-52899	3.3	14
60	A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. <i>Prostate</i> , 2016 , 76, 1303-11	4.2	14
59	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. <i>Prostate</i> , 2016 , 76, 1409-19	4.2	17
58	Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. <i>Prostate</i> , 2016 , 76, 810-22	4.2	30
57	Cross-Platform DNA Encoding for Single-Cell Imaging of Gene Expression. <i>Angewandte Chemie</i> , 2016 , 128, 9121-9124	3.6	
56	Cross-Platform DNA Encoding for Single-Cell Imaging of Gene Expression. <i>Angewandte Chemie - International Edition</i> , 2016 , 55, 8975-8	16.4	8

55	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 443-53	59.2	791
54	Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. <i>Nature Communications</i> , 2016 , 7, 13668	17.4	101
53	A proteolytic modification of AIM promotes its renal excretion. <i>Scientific Reports</i> , 2016 , 6, 38762	4.9	5
52	Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. <i>Clinical Epigenetics</i> , 2016 , 8, 97	7.7	23
51	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 1439-1456	6.7	79
50	Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2016 , 33, 325-37	4.7	13
49	Mismatch repair enzyme expression in primary and castrate resistant prostate cancer. <i>Asian Journal of Urology</i> , 2016 , 3, 223-228	2.7	12
48	SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 4698-708	12.9	105
47	ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. <i>Cancer Cell</i> , 2015 , 27, 797-808	24.3	75
46	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. <i>European Urology</i> , 2015 , 68, 1083-8	10.2	39
45	Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. <i>Neoplasia</i> , 2015 , 17, 385-99	6.4	156
44	Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort. <i>Prostate</i> , 2015 , 75, 1354-62	4.2	13
43	Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy. <i>PLoS ONE</i> , 2015 , 10, e0130565	5.7	39
42	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. <i>PLoS ONE</i> , 2015 , 10, e0132343	3.7	25
41	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765
40	The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma. <i>Molecular Cancer Research</i> , 2015 , 13, 339-47	6.6	9
39	A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. <i>Prostate</i> , 2015 , 75, 1206-15	4.2	47
38	DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance. <i>Oncotarget</i> , 2015 , 6, 2134-47	3.3	30

37	Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 1590-600	12.9	132
36	Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3705-15	2.2	169
35	Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. <i>Molecular and Cellular Biology</i> , 2014 , 34, 2017-28	4.8	74
34	The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. <i>Cancer Discovery</i> , 2014 , 4, 1310-25	24.4	271
33	Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. <i>Cancer Letters</i> , 2014 , 351, 272-80	9.9	15
32	Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. <i>PLoS ONE</i> , 2014 , 9, e104271	3.7	20
31	Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. <i>Nature Communications</i> , 2014 , 5, 4988	17.4	182
30	Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis. <i>PLoS ONE</i> , 2014 , 9, e111545	3.7	6
29	Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. <i>Oncotarget</i> , 2014 , 5, 9939-51	3.3	71
28	A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. <i>Cell</i> , 2013 , 154, 1074-1084	56.2	210
27	Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. <i>Clinical Cancer Research</i> , 2013 , 19, 2442-50	12.9	117
26	Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice. <i>PLoS Pathogens</i> , 2013 , 9, e1003774	7.6	125
25	A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. <i>Advances in Anatomic Pathology</i> , 2013 , 20, 39-44	5.1	15
24	Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. <i>Prostate</i> , 2013 , 73, 932-40	4.2	43
23	Androgen action and metabolism in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2012 , 360, 3-13	4.4	128
22	Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. <i>Nature Medicine</i> , 2012 , 18, 1359-68	50.5	542
21	Cellular senescence and cancer chemotherapy resistance. <i>Drug Resistance Updates</i> , 2012 , 15, 123-31	23.2	79
20	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. <i>Nature Genetics</i> , 2012 , 44, 685-9	36.3	1079

19	Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 644-6	2.2	96
18	INTRACRINE SYNTHESIS OF ANDROGENS BY PROSTATE CANCER IN RESPONSE TO ANDROGEN DEPRIVATION THERAPY 2011 , 193-218		2
17	Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. <i>Urology</i> , 2010 , 75, 407-13	1.6	48
16	Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 251-7	2.8	71
15	Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. <i>Cancer Research</i> , 2008 , 68, 4447-54	10.1	1046
14	Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2007 , 21, 3200-6	2.2	84
13	Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. <i>Cancer Research</i> , 2007 , 67, 5033-41	10.1	420
12	Cell type-specific analyses for identifying prostate cancer biomarkers. <i>Current Urology Reports</i> , 2006 , 7, 57-63	2.9	1
11	The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. <i>Cancer Research</i> , 2006 , 66, 794-802	10.1	332
10	A molecular correlate to the Gleason grading system for prostate adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 10991-6	11.5	219
9	Unconventional therapy for prostate cancer: good, bad or questionable?. <i>Nature Reviews Cancer</i> , 2003 , 3, 845-58	31.3	36
8	Dual-substrate specificity short chain retinol dehydrogenases from the vertebrate retina. <i>Journal of Biological Chemistry</i> , 2002 , 277, 45537-45546	5.4	146
7	The human (PEDB) and mouse (mPEDB) Prostate Expression Databases. <i>Nucleic Acids Research</i> , 2002 , 30, 218-20	20.1	22
6	The program of androgen-responsive genes in neoplastic prostate epithelium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 11890-5	11.5	356
5	Digital expression profiles of the prostate androgen-response program. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002 , 80, 13-23	5.1	36
4	Prostate cancer genomics. <i>Current Urology Reports</i> , 2001 , 2, 70-8	2.9	6
3	Toll receptors: an expanding role in our understanding of human disease. <i>Journal of Leukocyte Biology</i> , 2000 , 67, 767-773	6.5	70
2	Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics. <i>Electrophoresis</i> , 2000 , 21, 1823-31	3.6	68

1	Comprehensive analyses of prostate gene expression: Convergence of expressed sequence tag databases, transcript profiling and proteomics 2000 , 21, 1823	2
---	---	---